PA
MIRM icon

PharVision Advisers’s Mirum Pharmaceuticals MIRM Stock Holding History

PharVision Advisers’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,724
Closed -$273K – 889
2025
Q3 		$273K Buy
+3,724
New +$237K 0.15% 283

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PharVision Advisers's MIRM Position: Q4 2025 in Review

PharVision Advisers sold out of Mirum Pharmaceuticals (MIRM) in Q4 2025, closing a stake of 3,724 shares — an estimated $273K sold.

PharVision Advisers first reported a position in MIRM in Q3 2025 and held it in 1 quarter. The position peaked at $273K in Q3 2025. 281 funds tracked by Wall St. Rank hold MIRM as of Q4 2025.

  • PharVision Advisers reported no remaining Mirum Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 3,724 Mirum Pharmaceuticals shares in Q4 2025, an estimated $273K.
  • PharVision Advisers first reported a position in Mirum Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Mirum Pharmaceuticals position peaked at $273K in Q3 2025.
  • 281 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.